Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 9:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Eovist-enhanced MRI Clear all
Active, not recruiting Not applicable Interventional

Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions

NCT02156739
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver and Intrahepatic Bile Duct Disorder, Metastatic Malignant Neoplasm in the Liver, Primary Malignant Liver Neoplasm
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Gadobutrol, Gadoxetate Disodium
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 20, 2026, 9:39 PM EDT
Not listed No phase listed Observational

Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents

NCT01341132
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
MRI Scan of the Liver enhanced with Eovist
Procedure
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2011 · Synced Sep 20, 2026, 9:39 PM EDT
Recruiting Phase 2 Interventional

Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation

NCT06905054
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Liver Transplant, Complications, PSC, Biliary Strictures
Interventions
Fenofibrate (drug), Blood draw for the laboratory assessment, MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 20, 2026, 9:39 PM EDT
Completed Early Phase 1 Interventional Results available

The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma

NCT01673802
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
CT scan
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 20, 2026, 9:39 PM EDT
Completed Phase 4 Interventional

Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis

NCT04288323
View directory record Official record
Conditions
Liver Cancer, Liver Cirrhoses, Liver Carcinoma
Interventions
Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 20, 2026, 9:39 PM EDT
Not listed Not applicable Interventional

Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy

NCT01082224
View directory record Official record
Conditions
Liver Cancer
Interventions
iodinated contrast dye, motexafin gadolinium, Eovist-enhanced MRI
Drug · Other
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
9
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 20, 2026, 9:39 PM EDT
Terminated Phase 3 Interventional Results available

Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent

NCT02084628
View directory record Official record
Conditions
Magnetic Resonance Imaging
Interventions
Gadoxetate disodium (Eovist/Primovist, BAY86-4873)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 2 Months
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 20, 2026, 9:39 PM EDT
Recruiting Phase 2 Interventional

REGULUS: MRI-guided Adaptive SABR for Liver Cancers

NCT07223307
View directory record Official record
Conditions
Liver Cancer, Intrahepatic Cholangiocarcinoma, Liver Metastases, HCC
Interventions
MRI-guided adaptive stereotactic ablative body radiotherapy (SABR)
Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 20, 2026, 9:39 PM EDT
Recruiting Phase 2 Interventional

A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer

NCT06130280
View directory record Official record
Conditions
Colorectal Cancer, Liver Metastases
Interventions
MR Guided Single Fraction Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 20, 2026, 9:39 PM EDT
Completed No phase listed Observational Results available

Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.

NCT01043523
View directory record Official record
Conditions
Liver Neoplasms, Adenoma, Carcinoma, Liver Abscess
Interventions
Gadoxetic Acid Disodium (Eovist, BAY86-4873)
Drug
Lead sponsor
Bayer
Industry
Eligibility
2 Months to 18 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
5
States / cities
Palo Alto, California • New York, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2016 · Synced Sep 20, 2026, 9:39 PM EDT
Recruiting Phase 4 Interventional

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

NCT04373564
View directory record Official record
Conditions
Motor Function, Cognitive Function, Contrast Media
Interventions
Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Gadobenate dimeglumine, Gadodiamide, Gadoterate meglumine, Gadobutrol, Gadoteridol
Procedure · Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years to 64 Years
Enrollment
2,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
16
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 20, 2026, 9:39 PM EDT
Not listed Early Phase 1 Interventional

Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer

NCT03960788
View directory record Official record
Conditions
Cancer of the Prostate, Castration-resistant Prostate Cancer
Interventions
Gadoxetate Sodium
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Sep 20, 2026, 9:39 PM EDT
Completed Phase 2 Interventional Results available

Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer

NCT01867424
View directory record Official record
Conditions
Prostate Cancer
Interventions
Eovist
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Sep 20, 2026, 9:39 PM EDT
Completed Phase 1 Interventional

MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer

NCT02578602
View directory record Official record
Conditions
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage 0 Adult Hepatocellular Carcinoma, BCLC Stage A Adult Hepatocellular Carcinoma, BCLC Stage B Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Localized Resectable Adult Liver Carcinoma
Interventions
Gadoxetate Disodium, Magnetic Resonance Imaging
Drug · Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Sep 20, 2026, 9:39 PM EDT